CHICAGO — Avacincaptad pegol helped slow the rate of geographic atrophy growth compared with sham treatment, according to a study presented at Eyecelerator@AAO.
Dhaval Desai, PharmD, senior vice president and chief development officer at Iveric Bio, presented results from the GATHER2 study of avacincaptad pegol, which is part of a larger phase 3 clinical program.
“The GATHER program consisted of two clinical trials that looked at avacincaptad vs. sham for the treatment of geographic atrophy,” he said.
GATHER2, a phase 3 randomized, sham-controlled trial, evaluated efficacy and